Zogenix Inc (ZGNX.OQ)
* Zogenix announces closing of public offering of common stock, including full exercise of underwriters’ option to purchase additional shares Source text for Eikon: Further company coverage:
* Files for potential mixed shelf filing; size not disclosed - SEC filing Source text : (http://bit.ly/2xOgvG9) Further company coverage:
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .
* Analyst expects drug to become standard in Dravet treatment
* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome
Sept 29 Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.
* Zogenix provides corporate update and reports second quarter 2017 financial results
* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing
- GW Pharmaceuticals: Bull Thesis Strengthened And Further Upside Expected
- Zogenix (ZGNX) Presents At Stifel 2017 Healthcare Conference - Slideshow
- Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
- Zogenix's (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call Transcript
- Marinus Pharmaceuticals: The Next Big Thing In CNS
- Your Daily Pharma Scoop: Everybody's Gilead Problem, Halozyme's Further Progress, Ziopharm's Gene Therapy